| Drug General Information |
| Drug ID |
D0R7MJ
|
| Former ID |
DNC004185
|
| Drug Name |
PURPUROGALLIN
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H8O5
|
| Canonical SMILES |
C1=CC(=O)C(=C2C(=C1)C=C(C(=C2O)O)O)O
|
| InChI |
1S/C11H8O5/c12-6-3-1-2-5-4-7(13)10(15)11(16)8(5)9(6)14/h1-4,13,15-16H,(H,12,14)
|
| InChIKey |
WDGFFVCWBZVLCE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
L-selectin |
Target Info |
Inhibitor |
[2]
|
|---|
| P-selectin |
Target Info |
Inhibitor |
[2]
|
| mRNA of Bcl-x |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Cell adhesion molecules (CAMs)hsa04514:Cell adhesion molecules (CAMs)
|
|
Malaria
|
|
Staphylococcus aureus infectionhsa04014:Ras signaling pathway
|
|
NF-kappa B signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Jak-STAT signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Toxoplasmosis
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL9 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Leptin Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Notch Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
amb2 Integrin signalingil2_pi3kpathway:IL2 signaling events mediated by PI3K
|
|
IL3-mediated signaling events
|
|
Caspase Cascade in Apoptosis
|
|
EPO signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Cell surface interactions at the vascular wallR-HSA-114608:Platelet degranulation
|
|
Cell surface interactions at the vascular wallR-HSA-111453:BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasome
|
|
WikiPathways
|
Human Complement System
|
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Cell surface interactions at the vascular wallWP2806:Human Complement System
|
|
Spinal Cord Injury
|
|
Cell surface interactions at the vascular wallWP364:IL-6 signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
Apoptosis
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
TNF alpha Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
Intrinsic Pathway for Apoptosis
|
|
Apoptosis Modulation and Signaling
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007041) |
|---|
| REF 2 | J Med Chem. 2007 Mar 22;50(6):1101-15. Epub 2007 Feb 16.Rational design of novel, potent small molecule pan-selectin antagonists. |
|---|
| REF 3 | J Med Chem. 2003 Sep 25;46(20):4259-64.Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. |
|---|
